Table 4 Comparison of treatment versus placebo groups for the association of trachomatous trichiasis (TT) severity at baseline with the incidence of postoperative recurrence at 3, 6, and 12 months.
| TT severity at baseline | 3 month TT incident recurrence* | 6 month TT incident recurrence* | 12 month TT incident recurrence* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment group (%) | Placebo group (%) | p Value† | Treatment group (%) | Placebo group (%) | p Value† | Treatment group (%) | Placebo group (%) | p Value† | |
| Epilated‡ (no eyelashes) | 1/17 (5.9) | 0/16 (0) | NS (1.000) | 3/15 (20.0) | 5/14 (35.7) | NS (0.427) | 2/12 (16.6) | 0/9 (0) | NS (0.872) |
| Minor TT (⩽5 eyelashes) | 1/25 (4.0) | 0/33 (0) | NS (0.431) | 6/22 (27.3) | 3/30 (10.0) | NS (0.144) | 0/15 (0) | 0/27 (0) | NS |
| Major TT (>5 eyelashes) | 2/17 (11.8) | 0/11 (0) | NS (0.505) | 1/16 (6.3) | 8/14 (57.1) | 0.004 | 1/16 (6.3) | 0/5 (0) | NS (1.000) |
| Total | 4/59 (6.8) | 0/60 (0) | NS (0.057) | 10/53 (18.9) | 16/58 (27.6) | NS (0.279) | 3/43 (7.0) | 0/41 (0) | NS (0.241) |
NS, not significant.
*Denominator reflects number of eyelids; TT incident recurrence compared with baseline; Surgical failures were excluded from this table; surgical failure was defined as ⩾5 lashes at the lateral margins of the surgical incision (instead of centrally located) and touching the globe of the eye at the 3 month follow up; TT recurrence was defined as ⩾1 lash touching the globe of the eye following TT surgery, excluding surgical failures.
†χ2 test; p values reflected the differences in incidence rates between treatment and placebo groups according to TT status at baseline, after excluding surgical failures; statistical significance (p⩽0.05).
‡Epilated cases defined as eyelids that had entropion but no lashes touching the globe, not included in the minor or major categories.